Berecki G , Daly NL , Huang YH , Vink S , Craik DJ , Alewood PF , Adams DJ .

Adams, Analgesic conotoxins: block and G protein-coupled receptor modulation of N-type (Ca(V) 2.2) calcium channels. 2012, Pubmed

Adams, Analgesic conotoxins: block and G protein-coupled receptor modulation of N-type (Ca(V) 2.2) calcium channels. 2012, Pubmed
Adams, Omega-conotoxin CVID inhibits a pharmacologically distinct voltage-sensitive calcium channel associated with transmitter release from preganglionic nerve terminals. 2003, Pubmed , Xenbase
Alexander, The Concise Guide to PHARMACOLOGY 2013/14: ion channels. 2013, Pubmed
Altier, Targeting Ca2+ channels to treat pain: T-type versus N-type. 2004, Pubmed
Andersson, Label-free kinetic binding data as a decisive element in drug discovery. 2006, Pubmed
Atkinson, Structural and dynamic characterization of omega-conotoxin MVIIA: the binding loop exhibits slow conformational exchange. 2000, Pubmed
Barlow, Antagonist inhibition curves and the measurement of dissociation constants. 1997, Pubmed
Berecki, Analgesic (omega)-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels. 2010, Pubmed , Xenbase
Bingham, Drugs from slugs--past, present and future perspectives of omega-conotoxin research. 2010, Pubmed
Bulaj, Folding of conotoxins: formation of the native disulfide bridges during chemical synthesis and biosynthesis of Conus peptides. 2008, Pubmed
Callaghan, Analgesic alpha-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation. 2008, Pubmed , Xenbase
Catterall, Voltage-gated calcium channels. 2011, Pubmed
Catterall, International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. 2005, Pubmed
Christopoulos, G protein-coupled receptor allosterism and complexing. 2002, Pubmed
Clark, The engineering of an orally active conotoxin for the treatment of neuropathic pain. 2010, Pubmed
Craik, Chemical modification of conotoxins to improve stability and activity. 2007, Pubmed
Craik, The cystine knot motif in toxins and implications for drug design. 2001, Pubmed
Cuny, γ-Aminobutyric acid type B (GABAB) receptor expression is needed for inhibition of N-type (Cav2.2) calcium channels by analgesic α-conotoxins. 2012, Pubmed
Hatakeyama, Differential nociceptive responses in mice lacking the alpha(1B) subunit of N-type Ca(2+) channels. 2001, Pubmed
Jaggi, Animal models of neuropathic pain. 2011, Pubmed
Jayamanne, Spinal actions of ω-conotoxins, CVID, MVIIA and related peptides in a rat neuropathic pain model. 2013, Pubmed
Kilkenny, Animal research: reporting in vivo experiments: the ARRIVE guidelines. 2010, Pubmed
Kim, Hydroxyl group of Tyr13 is essential for the activity of omega-conotoxin GVIA, a peptide toxin for N-type calcium channel. 1994, Pubmed
Koradi, MOLMOL: a program for display and analysis of macromolecular structures. 1996, Pubmed
Lewis, Conus venom peptide pharmacology. 2012, Pubmed
Lewis, Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. 2000, Pubmed , Xenbase
Li, Up-regulation of Cavβ3 subunit in primary sensory neurons increases voltage-activated Ca2+ channel activity and nociceptive input in neuropathic pain. 2012, Pubmed
McGivern, Targeting N-type and T-type calcium channels for the treatment of pain. 2006, Pubmed
McGrath, Guidelines for reporting experiments involving animals: the ARRIVE guidelines. 2010, Pubmed
Miljanich, Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. 2004, Pubmed
Motin, Omega-conotoxin CVIB differentially inhibits native and recombinant N- and P/Q-type calcium channels. 2007, Pubmed , Xenbase
Mould, The alpha2delta auxiliary subunit reduces affinity of omega-conotoxins for recombinant N-type (Cav2.2) calcium channels. 2004, Pubmed , Xenbase
Newcomb, Bioavailability of Ziconotide in brain: influx from blood, stability, and diffusion. 2000, Pubmed
Nielsen, Effects of chirality at Tyr13 on the structure-activity relationships of omega-conotoxins from Conus magus. 1999, Pubmed
Olivera, Calcium channel diversity and neurotransmitter release: the omega-conotoxins and omega-agatoxins. 1994, Pubmed
Sadeghi, Novel ω-conotoxins from C. catus reverse signs of mouse inflammatory pain after systemic administration. 2013, Pubmed
Schmidtko, Ziconotide for treatment of severe chronic pain. 2010, Pubmed
Schnölzer, In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. 1992, Pubmed
Schroeder, N-type calcium channel blockers: novel therapeutics for the treatment of pain. 2006, Pubmed
Scott, Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. 2002, Pubmed
Scroggs, Calcium current variation between acutely isolated adult rat dorsal root ganglion neurons of different size. 1992, Pubmed
Snutch, Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. 2005, Pubmed
Stocker, Preferential interaction of omega-conotoxins with inactivated N-type Ca2+ channels. 1997, Pubmed , Xenbase
Swinney, The role of binding kinetics in therapeutically useful drug action. 2009, Pubmed
Terlau, Conus venoms: a rich source of novel ion channel-targeted peptides. 2004, Pubmed
Vink, Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain. 2012, Pubmed
Wallace, Ziconotide combination intrathecal therapy: rationale and evidence. 2010, Pubmed
Wermeling, Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. 2003, Pubmed
Williams, Ziconotide: an update and review. 2008, Pubmed
Wishart, 1H, 13C and 15N random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest-neighbor effects. 1995, Pubmed
Yaksh, Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. 2012, Pubmed
Zamponi, Role of voltage-gated calcium channels in ascending pain pathways. 2009, Pubmed